Alphatec Holdings Enters $200M Credit Deal, Terminates Prior Loan

Alphatec Holdings, Inc., a Carlsbad, California-based medical device firm, filed an 8-K with the Securities and Exchange Commission on May 5, 2026, reporting entry into a material credit agreement, termination of a prior financing deal, quarterly operating results, creation of a new financial obligation, and related exhibits.

The filing affects Alphatec's financial structure and operations, involving a new $200 million term loan credit facility per Item 1.01 details. This impacts the company's approximately 500 employees and its network of surgeons using Alphatec's spine surgery products, with the new funding supporting ongoing development of devices serving over 10,000 procedures annually based on the company's prior annual reports.

The quarterly results under Item 2.02 show revenue of $120 million for the first quarter of 2026, up 15% from the previous year, but a net loss of $15 million, reflecting costs from product launches.

Prior to the filing, Alphatec operated under a 2023 credit agreement with Squadron Capital for $150 million, which provided revolving credit for working capital. The new state, effective May 4, 2026, replaces this with a term loan from MidCap Financial Trust, carrying an interest rate of SOFR plus 6.5% and a maturity date of May 4, 2031, per the agreement terms quoted in Item 1.01.

The termination under Item 1.02 ends the Squadron deal immediately upon the new facility's closing, eliminating prior covenants restricting acquisitions.

The new credit facility creates a direct financial obligation under Item 2.03, requiring quarterly principal payments starting September 30, 2026, and compliance with financial covenants including a minimum revenue threshold of $450 million annually.

This triggers a Form 10-Q filing deadline of May 15, 2026, for detailed financial statements, and mandates exhibit filings under Item 9.01, including the full credit agreement text available within four business days. Lenders now hold rights to accelerate repayment if defaults occur, potentially affecting future equity offerings.

Alphatec last reported a similar financing restructure in its August 2024 8-K, which expanded borrowing capacity amid acquisitions of spine technology firms. The company has filed three 8-Ks related to debt obligations in the past 12 months, aligning with its growth strategy in the $15 billion global spine market.